Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.49 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | PRMT3 | O60678 | 3/20 | 0.35 |
| ▸ | AKT1 | P31749 | 3/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31008989 | 0.80 | SLC6A4 (0.49) | — | |
| SCHEMBL29218751 | 0.80 | SLC6A4 (0.49) | — | |
| SCHEMBL29218531 | 0.76 | OPRL1 (0.38) | — | |
| SCHEMBL29218693 | 0.73 | KDM1A (0.42) | — | |
| SCHEMBL28187441 | 0.72 | PRKCZ (0.39) | PRKCZAKT1 | |
| SCHEMBL1572041 | 0.71 | SMYD3 (0.59) | SMYD3ROCK1PRMT3 | |
| SCHEMBL1705673 | 0.69 | IKBKB (0.63) | SMYD3PRKCZROCK1IKBKBAKT1 | |
| SCHEMBL1705706 | 0.69 | IKBKB (0.63) | SMYD3PRKCZROCK1IKBKBAKT1 | |
| SCHEMBL1705322 | 0.69 | IKBKB (0.63) | SMYD3PRKCZROCK1IKBKBAKT1 | |
| SCHEMBL28551882 | 0.69 | OPRL1 (0.34) | ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056568-A1 | Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056568-A1 | Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives | MYLK2, MYLK, MYLK3 | SMYD3 2923/4885PRKCZ 53/4885ROCK1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.